Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales ...

Macroeconomic uncertainties could impact spending in academia and biopharma.

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Reports Q4 revenue $165.0M, consensus $164.98M. “In 2024, we launched major new products across all three of our platforms and we made changes ...

Genomics, Inc. , a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for ...

Genomics (TXG) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.41 per share a year ago. These figures are adjusted ...

X Genomics Inc . (NASDAQ:TXG) reported its Q4 2024 earnings, revealing a larger-than-expected loss per share and a decline in revenue compared to the previous year. The company posted an EPS of -$0.40 ...

Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of California lost 18% and 15%, respectively.

GeneDx , a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 45th Annual TD Cowen Health Care Conference from ...

Detailed price information for Super Micro Computer (SMCI-Q) from The Globe and Mail including charting and trades.

Trump Holds Call With Putin to Start Talks on Ending Ukraine War President Trump said he had “a lengthy and highly productive” call with President Vladimir Putin of Russia, their first ...

Get dialed in every Tuesday & Friday with quick updates on the world of crypto ...